Glycine

Glycine

SCHEMBL4661565

NCC(=O)[O-].[Al+3].[OH-].[OH-]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycine SCHEMBL223345 0.96 CA4 (0.47)
Glycine SCHEMBL2473796 0.93 CA4 (0.39)
Glycine SCHEMBL2161269 0.92 CA4 (0.44)
Glycine SCHEMBL5689090 0.92 CA4 (0.44)
Glycine SCHEMBL5943682 0.92 CA4 (0.44)
Glycine SCHEMBL6753488 0.92 CA4 (0.44)
Glycine SCHEMBL4728488 0.92 CA4 (0.44)
Glycine SCHEMBL2405749 0.92
Glycine SCHEMBL3121145 0.92 CA4 (0.44)
Glycine SCHEMBL5187484 0.92 CA4 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4446300-B1 PREPARATION METHODS OF ALUMINIUM FLUORIDE COMPLEXES TRASIS S A (BE) 2025-11-26 EP claimed
EP-4446300-A1 PREPARATION METHODS OF ALUMINIUM FLUORIDE COMPLEXES Trasis S.A. (BE) 2024-10-16 EP claimed
US-20260116897-A1 PREPARATION METHODS OF ALUMINIUM FLUORIDE COMPLEXES TRASIS S A (BE) 2026-04-30 US disclosed
EP-4446300-B1 PREPARATION METHODS OF ALUMINIUM FLUORIDE COMPLEXES TRASIS S A (BE) 2025-11-26 EP disclosed
EP-4446300-A1 PREPARATION METHODS OF ALUMINIUM FLUORIDE COMPLEXES Trasis S.A. (BE) 2024-10-16 EP disclosed
EP-1627866-B1 CARBOXYLIC ACID COMPOUND AND MEDICINE CONTAINING THE SAME KOWA CO (JP) 2008-12-24 EP disclosed
US-20070010700-A1 Safety containers for biologically active substances and method for producing said container BAXTER INTERNATIONAL INC (US) 2007-01-11 US disclosed
US-7109242-B2 Carboxylic compound and medicine comprising the same KOWA COMPANY, LTD. (JP) 2006-09-19 US disclosed
EP-1627866-A1 CARBOXYLIC ACID COMPOUND AND MEDICINE CONTAINING THE SAME Kowa Company Ltd. (JP) 2006-02-22 EP disclosed
EP-1585679-A1 SAFETY CONTAINERS FOR BIOLOGICALLY ACTIVE SUBSTANCES AND METHOD FOR PRODUCING SAID CONTAINER Baxter Healthcare S.A. (CH) 2005-10-19 EP disclosed
US-20050009909-A1 Carboxylic compound and medicine comprising the same KOWA COMPANY, LTD. (JP) 2005-01-13 US disclosed
WO-2004063036-A1 SAFETY CONTAINERS FOR BIOLOGICALLY ACTIVE SUBSTANCES AND METHOD FOR PRODUCING SAID CONTAINER BAXTER HEALTHCARE S.A. (CH) 2004-07-29 WO disclosed
EP-0241804-B1 PRESERVED ANTACID PREPARATIONS BAYER AG (DE) 1992-01-15 EP disclosed
EP-0241804-A2 Preserved antacid preparations BAYER AG (DE) 1987-10-21 EP disclosed